A 70 percent ownership position in Armed Cell Therapeutics B.V. — a Belgian developer of cancer cell therapies — is set to pass to Mankind Pharma through a transaction valued at EUR 48 million. A regulatory filing with the exchanges disclosed that Mankind Pharma (Netherlands) B.V., a wholly owned subsidiary, would serve as the vehicle through which the deal is structured.
With this agreement, Mankind enters the CAR-T therapy space for the first time. Revenue generated by the Delhi-headquartered firm has, until now, drawn predominantly from pharmaceutical formulations and consumer healthcare products sold within India.
A supplementary injection of as much as EUR 45 million into Mankind Netherlands received the board's approval alongside the other measures. Contributions may arrive in a single payment or spread across several instalments. Combining that earlier-approved EUR 5 million allocation with the newly sanctioned funds brings the subsidiary's overall investment ceiling to EUR 50 million.
A EUR 48 million allocation toward Armed Cell Therapeutics — documented in the filing under the shorthand ACTx — forms the core of how Mankind Netherlands plans to deploy those funds. Funds are to be disbursed across a series of instalments, with the full amount settled in cash.
According to the document lodged with regulators, the definitive agreement will govern when the acquisition is to be concluded. Where the host country's laws impose an approval requirement, the necessary filings with relevant authorities will be made. Mankind Netherlands will remain under full ownership, with the company's shareholding in that subsidiary left intact. Mankind Netherlands' stake in ACTx falls outside the definition of a related party transaction, the filing noted.
Court documents show the entity was structured to hold research and development assets while also pursuing opportunities in specialised therapy markets. Partnerships of this kind may take shape through shared ventures or the purchase of targeted ownership stakes. Having only recently been established, the entity has yet to record any revenue.
At the heart of the company's development portfolio sit a set of CAR-T therapies that its researchers have configured to deliver additional tumour-targeting agents alongside the cell-based treatment itself — a design the firm internally labels "armed." In this therapy, T cells drawn from the patient's own body are laboratory-modified to locate and destroy tumour cells. Among the therapies advancing through its development portfolio, two front-running programmes take aim at non-Hodgkin lymphoma and small cell lung cancer.
According to the filing, CAR-T therapies have altered how certain blood cancers are treated. The report acknowledged that relapses remain a documented outcome in a portion of patients, attributed to factors including insufficient cellular persistence, exhaustion of the introduced cells, or the presence of tumour cells that do not respond to treatment. When it comes to treating solid tumours, the dense and hostile tissue surroundings can block therapeutic cells from reaching their targets or carrying out their intended role.
Built into ACTx's methodology is a process of loading cells with extra molecular components designed to bolster and prolong their functional output. Targeting multiple cancer antigens at once forms part of the treatment's design, with that approach intended to reduce the likelihood of tumour cells finding a way to evade detection. Beyond generating CAR-T cells externally, ACTx has outlined plans to produce them directly within the patient's body as one of several additional avenues under exploration.
Its registered office sits in Belgium, with additional operations running out of the Netherlands. Pittsburgh, in the United States, serves as the home for the organisation's pre-clinical studies and broader research programme. Development work at the preliminary stage is distributed across sites in Europe, Asia, and the United States.
Ranked among India's top pharmaceutical companies by domestic reach, Mankind Pharma directs the bulk of its commercial activity toward the home market. Its portfolio spans both short-term and long-term treatment categories, covering disease areas such as anti-infectives, cardiovascular conditions, gastrointestinal disorders, diabetes management, neurological and central nervous system conditions, gynaecology, and respiratory health. Among its offerings are consumer health goods spanning contraceptives — both barrier-type and emergency formulations — alongside pregnancy testing products, digestive relief powders, and a range of vitamin and mineral preparations.
Mankind Pharma's stock slipped 2.53 percent during intraday trading on October 16. Over the past month, that stock's value climbed 2.1 percent. Over the twelve months to the present, Mankind Pharma's equity value has slipped by 6.5 percent.
